Side Effects of Calcium Channel Blockers

R. Patterson Russell

SUMMARY Calcium channel blocking drugs are a chemically heterogenous group, so it might be expected that their effects on vascular smooth muscle, cardiac contractility, and conduction tissue may differ. However, the majority of adverse reactions are predictable from their pharmacological actions and may be conveniently grouped in the following categories: 1) vasodilatation, 2) negative inotropic effects, 3) conduction disturbances, 4) gastrointestinal effects, 5) metabolic effects, and 6) drug interactions. Vasodilatory symptoms, namely, dizziness, headaches, flushing sensation, and palpitation, are more likely with nifedipine. Peripheral edema is also common with nifedipine, but the mechanism is uncertain. For a given degree of vasodilation, the greatest negative inotropic effect is seen with verapamil first, diltiazem second, and nifedipine last. Calcium channel blocking drugs are contraindicated in hypertensive patients with second and third degree heart block, sick sinus syndrome, and severe heart failure. Verapamil and diltiazem have a significant effect on cardiac conduction, whereas nifedipine, in therapeutic doses, does not. Local gastrointestinal symptoms, such as nausea and constipation, are common with verapamil. None of the calcium channel blocking drugs have been reported to adversely affect lipid or protein metabolism. However, nifedipine, verapamil, and diltiazem in high doses may inhibit liberation of insulin. The significance of this finding needs to be explored further in hypertensive diabetics. Serum digoxin levels have been shown to increase after administration of verapamil and nifedipine, but there is no evidence that this change has any clinical relevance. The combination of calcium channel blocking drugs and β-blockers may be beneficial in hypertensive patients with normal heart function but should be avoided in the presence of cardiac function impairments. (Hypertension 11 [Suppl II]: II-42-11^4, 1988)

KEY WORDS nifedipine • nitrendipine • verapamil • diltiazem • side effects

SINCE the hemodynamic hallmark of essential hypertension is an increased total peripheral resistance, the logical treatment choice is a drug that promotes arteriolar vasodilatation. Calcium entry blockers all reduce the entrance of calcium ions into vascular smooth muscle cells, and their antihypertensive effect has been documented since 1968. However, these agents are heterogenous, differing in chemical structure and intracellular actions as well as in physiological effects. Over three dozen of these compounds are either being prescribed for patients worldwide or are under active clinical investigation; though at present, verapamil is the only calcium channel blocking drug that has received FDA approval for the treatment of hypertension in the United States.

Despite the long-standing use of these agents, it is difficult to compare quantitatively the adverse reactions experienced individually because the recording of side effects has not been standardized and because there have been few direct comparisons between the agents. One additional problem that confounds this reviewer’s task is that the cumulative frequency of adverse effects of calcium channel blocking drugs more often than not is derived from studies in patients with coronary artery disease, and it may not be justifiable to compare side effects of different drugs in different diseases. Recognizing these limitations and the fact that essential hypertension is often an asymptomatic disease, the frequency of adverse effects may actually be greater in hypertensive patients as compared with the reported frequency in patients with coronary insufficiency.

Calcium channel blocking drugs may be divided into two pharmacological classes: 1) those that possess both vasodilating and cardiodepressing actions, such as verapamil, diltiazem, bepridil, gallopamil, perhexiline, and tiampamil; and 2) those that possess vasodilating but not cardiodepressing actions, such as dihydropyridines, including nifedipine, nitrendipine, nisoldipine, nicardipine, and felodipine, and cinnarizine, flunarizine, and lidoflazaine.

The structures of three of the most commonly used calcium channel blockers are shown in Figure 1.

The majority of adverse reactions to calcium channel blockers are predictable from their pharmacological actions. Moreover, because of the heterogeneity of
these compounds, they differ in their effects on vascular smooth muscle, cardiac contractility, and conduction tissue.

Major adverse reactions associated with calcium channel blocking drugs may be conveniently grouped in the following categories: 1) vasodilation that is characterized by headaches, flushing, palpitations, peripheral edema, and hypotension; 2) negative inotropic effects that contraindicate the use of some calcium channel blockers in the presence of severe left ventricular dysfunction or sick sinus syndrome and second or third degree atrioventricular block; 3) conduction disturbances, specifically supraventricular tachycardia; 4) gastrointestinal effects, such as constipation, diarrhea, and nausea; and 5) metabolic effects; and drug interactions associated with 6) cardiac glycosides and 7) β-blockers. Table 1 ranks the three most commonly used calcium channel blockers used in the United States, nifedipine, verapamil, and diltiazem, with regard to each of the above mentioned categories of adverse reactions.

Nifedipine has the strongest vasodilatory effect for coronary artery disease and seems to be dependent on the dose and rate of absorption. Whether this is also true for hypertension has not been established. Verapamil, for a given degree of vasodilation, has the greatest negative inotropic effect and effect on cardiac conduction. A high frequency of constipation has been attributed to verapamil, ranging from 12 to 42%, though a few patients have discontinued the drug for this reason. Edema is a common side effect of the calcium antagonists, particularly with nifedipine. While the mechanism has not been defined precisely, it is believed that this is on the basis of precapillary dilatation and postcapillary reflexive constriction. None of the calcium channel blocking drugs have been reported to adversely affect lipid or potassium metabolism. All three agents in high dose may inhibit liberation of insulin, though basal insulin secretion in healthy volunteers is not significantly influenced by diltiazem, nifedipine, or verapamil. A reversible hyperglycemia has been reported in patients with maturity onset diabetes mellitus treated with nifedipine, and short-term administration of nifedipine to subjects with a normal glucose tolerance resulted in significant glucose intolerance. However, Schulte and associates were unable to find any significant changes in serum glucose or insulin in nondiabetic hypertensive subjects treated for 8 weeks with nifedipine and diltiazem.

There are two areas of interest with regard to potential drug interactions. In patients treated with digoxin, the serum digoxin level is raised after administration of verapamil or nifedipine. While the effect of verapamil is dose dependent and greater than nifedipine, there is no evidence that the increase in digoxin level by verapamil or nifedipine has any clinical relevance. Second, in patients whose disease is not adequately controlled by β-blockers alone, the addition of a calcium channel blocker may be beneficial. This is particularly true for nifedipine but may be contraindicated for verapamil. Even though beneficial effects of the latter combination have been reported, administration of verapamil to patients treated with β-blocking drugs has the potential for causing severe conduction disturbances as well as negative inotropic effects. Additional long-term studies are needed to resolve this drug interaction issue.

Table 2 is adapted from McMahon and depicts the overall incidence of adverse reactions for nifedipine, verapamil, and diltiazem and lists the leading reactions associated with each drug(s). The data in this table are based upon experience with 2100 patients studied for coronary insufficiency. The same patient may be counted under one or more reactions, and it should be emphasized that these were patients with coronary insufficiency. There is currently very little data that permit one to compare directly the effects of these three calcium channel blockers in treatment of patients with essential hypertension.

Data concerning adverse reactions occurring in hypertensive patients treated with another calcium channel blocking drug, nitrendipine, a dihydropyridine derivative similar in action to nifedipine, were presented.
recently at the Second International Nitrendipine Symposium held in Lisbon, Portugal, on April 17-19, 1986. Weber reported on 1 year’s experience with a multicenter study with nitrendipine in 329 patients with essential hypertension. Diastolic blood pressure was recorded as less than 105 mm Hg in 256, between 105 and 114 mm Hg in 77, and greater than 115 mm Hg in 2 patients. Forty-five patients, or 14%, did not complete the study, but only one third or 4.7% were discontinued because of adverse reactions. Corsing et al. reported a total of 105 side effects in 61 of 211 hypertensive patients treated with nitrendipine for 300 or more days. Headache was seen most frequently in 42% of patients on long-term therapy with verapamil at 360 mg daily being treated for chronic stable angina and hypertension. According to Subramanian and Raftery, 13 the most common major side effects seen in 250 patients on long-term therapy with verapamil at 360 mg daily being treated for chronic stable angina and hypertension are a prolongation of the PR interval greater than 0.24 seconds (3.2%), junctional escape rhythm (1.6%), and intraventricular conduction defect (1.2%). However, only five patients had to be withdrawn from treatment because of these side effects.

Of the three calcium channel blocking drugs available in the United States, diltiazem appears to have the fewest reported adverse effects. However, an idiosyn-

**Table 2. Percentage of Adverse Reactions to Calcium Channel Blockers**

<table>
<thead>
<tr>
<th>Adverse effect</th>
<th>Nifedipine</th>
<th>Verapamil</th>
<th>Diltiazem</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall incidence</td>
<td>17.0</td>
<td>8.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Dizziness or light-headedness</td>
<td>10</td>
<td>3.6</td>
<td>—</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>10</td>
<td>1.7</td>
<td>2.4</td>
</tr>
<tr>
<td>Headache</td>
<td>10</td>
<td>1.8</td>
<td>2.0</td>
</tr>
<tr>
<td>Flushing or heat sensation</td>
<td>10</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Transient hypotension</td>
<td>5</td>
<td>2.9</td>
<td>—</td>
</tr>
<tr>
<td>Nausea</td>
<td>10</td>
<td>1.6</td>
<td>2.7</td>
</tr>
<tr>
<td>Constipation</td>
<td>—</td>
<td>6.3</td>
<td>—</td>
</tr>
<tr>
<td>Bradycardia</td>
<td>1.1</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>—</td>
<td>1.8</td>
<td></td>
</tr>
</tbody>
</table>

*Based upon 2100 patients studied for angina. Adapted from McMahon with permission.

**Table 3. Adverse Effects in 344 Hypertensive Patients Treated with Nitrendipine**

<table>
<thead>
<tr>
<th>Adverse effect</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headaches</td>
<td>48</td>
<td>13.9</td>
</tr>
<tr>
<td>Flushing</td>
<td>25</td>
<td>7.3</td>
</tr>
<tr>
<td>Palpitation</td>
<td>18</td>
<td>5.2</td>
</tr>
<tr>
<td>Ankle swelling</td>
<td>8</td>
<td>2.3</td>
</tr>
</tbody>
</table>

Data taken collectively from References 7–11.

**References**

13. Subramanian B, Raftery EB: The role of verapamil in chronic stable angina and hypertension. 30th Annual Scientific Session, American College of Cardiology; 1981 March 15–19; San Francisco
Side effects of calcium channel blockers.
R P Russell

_Hypertension_. 1988;11:II42
doi: 10.1161/01.HYP.11.3_Pt_2.II42

_Hypertension_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1988 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/11/3_Pt_2/II42

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in_Hypertension_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to_Hypertension_ is online at:
http://hyper.ahajournals.org/subscriptions/